Onco-Innovations Partners with Kuano to Apply Quantum Computing to PNKP Inhibitor Development
核心洞察
Onco-Innovations Limited (搜索) has initiated a pilot project with Kuano Ltd (搜索). to accelerate development of its PNKP (搜索) Inhibitor Technology using quantum-ready analytics and AI-driven compound design.
The collaboration will deploy Kuano's quantum molecular modeling platform to provide detailed characterization of how the A83B4C63 (搜索) compound interacts with PNKP (搜索), including binding poses and inhibition mechanisms.
The pilot project runs through Q4 2025 and aims to deliver validated platform outputs, structural binding models, and mechanistic hypotheses to inform next-generation therapeutic design.
Onco-Innovations Limited (搜索) has announced a strategic collaboration with quantum biotechnology company Kuano Ltd (搜索). to accelerate the development of its PNKP (搜索) Inhibitor Technology through advanced computational platforms. The pilot project represents a significant step in applying quantum computing and artificial intelligence to oncology drug discovery.
Quantum-Enhanced Drug Discovery Platform
The collaboration will leverage Kuano's quantum-ready analytics platform to deepen structural insights into PNKP (搜索) inhibition. Kuano's advanced quantum molecular modeling is expected to provide detailed characterization of how Onco's lead compound A83B4C63 (搜索) interacts with PNKP, including binding poses, conformational changes, and the underlying mechanism of inhibition.
"We are thrilled to apply Kuano's quantum-enabled platform to a challenging oncology target in this exciting collaboration with Onco-Innovations. By bringing quantum precision to the molecular level, we aim to bring new insights to PNKP (搜索) inhibition and help accelerate the design of next-generation therapeutics," stated Vid Stojevic, CEO and Co-Founder of Kuano.
PNKP Inhibitor Technology Advancement
The initiative builds upon Onco's ongoing efforts to enhance discovery and evaluation of its proprietary PNKP (搜索) inhibitor platform. Through advanced molecular modeling and AI-driven compound design, the program has refined compound architecture, simplified synthesis pathways, and expanded the library of optimized analogs centered on the A83B4C63 (搜索) scaffold.
These developments strengthen the potential for developing more selective and potent inhibitors while accelerating the transition of PNKP (搜索) candidates toward preclinical validation. The integration of Kuano's quantum-level analytics within Onco's AI-enabled discovery environment aims to create a streamlined framework from modeling to validation and synthesis.
Project Timeline and Expected Outcomes
The pilot project will run through the fourth quarter of 2025 and is expected to deliver validated platform outputs, structural binding models, and mechanistic hypotheses. The results will inform follow-on initiatives in quantum-ready QSAR modeling, toxicity mapping, and generative compound design across the broader PNKP (搜索) Inhibitor Technology pipeline.
"Our work with Kuano reflects a clear strategic direction for Onco-Innovations to lead in next-generation oncology through the integration of advanced computational and experimental science. This pilot represents an important step toward realizing the full potential of our PNKP (搜索) Inhibitor Technology," stated Thomas O'Shaughnessy, CEO of Onco-Innovations.
Technology Platform Integration
Kuano operates as a next-generation biotechnology company applying quantum mechanics and artificial intelligence to structure-based drug discovery. Its proprietary platform models enzyme dynamics and transition states at quantum resolution, enabling the design of novel, selective compounds through predictive molecular simulation.
The collaboration focuses initially on Onco's PNKP (搜索)-targeting compounds, with the quantum-enhanced approach designed to guide structure optimization and generate candidates for next-generation therapeutics. Onco-Innovations holds an exclusive worldwide license to patented technology that targets solid tumors through PNKP inhibition.